Johnson & Johnson presents clinical data for TECNIS PureSee IOL at ASCRS meeting

Johnson & Johnson will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting, April 10-13 in Washington, DC. TECNIS PureSee IOL is J&J’s next-generation Extended Depth of Focus IOL, which demonstrates excellent clinical outcomes and provides significantly improved range of vision* and reduced visual symptoms compared to a monofocal IOL.1 “The data presented at ASCRS 2026 confirms that TECNIS PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances,” said Paul Lisenby, Global Head of Research and Development, Vision. “This evidence underscores our commitment to advancing innovation through rigorous clinical research-extending the range of vision for our patients and reinforcing surgeon confidence.” Notable findings for TECNIS PureSee IOL: Results from a real-world, post-market observation study among 293 patients and across 19 sites in Europe and Asia-Pacific showed that TECNIS PureSee IOL provides excellent clinical outcomes, low bothersome visual symptoms, and high patient satisfaction with limited spectacle use. TECNIS PureSee IOL also demonstrated a high tolerance to post-operative refractive errors. The following datasets from this study will be highlighted at ASCRS: Real-World Quality of Vision Outcomes in Patients Implanted with a Purely Refractive Extended Depth of Focus IOL – Brian Schwam, MD. Data showed mean binocular uncorrected distance vision of 20/19, intermediate and distance corrected vision of 20/26. Most patients experienced little or no bothersome glare, halos and starbursts, respectively. Real-World Spectacle Independence and Visual Outcomes in Patients Implanted with a Purely Refractive Extended Depth of Focus IOL – Naren Shetty, MS PhD. Data showed mean binocular uncorrected distance vision of 20/19 and best corrected distance vision of 20/18. Spectacle independence was reported in 96% of patients for distance, 95% for intermediate, and 61% for near vision. There was 93% patient satisfaction across all distances. Real-world Performance of New Purely Refractive Extended Depth of Focus IOL in Patients with Residual Post-op Refractive Error – Habeeb Ahmad, MD MS. Data showed mean binocular uncorrected distance vision was 20/19 among ametropic and emmetropic patients. Most patients reported spectacle independence at a distance. 95% of ametropic and 92% of emmetropic patients were satisfied with their uncorrected overall vision. Results from a U.S. prospective, randomized clinical trial among 200 patients and across nine sites showed that TECNIS PureSee IOL provides high-quality distance vision and significantly improved intermediate vision vs monofocal control. Results also showed some near vision gained and contrast sensitivity comparable to an aspheric monofocal IOL. There were low levels of visual symptoms. The following datasets from this study will be highlighted at ASCRS: Quality of Vision Clinical Outcomes for a New Extended Depth of Focus Intraocular Lens; Eric Donnenfeld, MD. Data showed low visual disturbances and improved intermediate and near vision compared to a monofocal IOL. Depth of Focus and Visual Performance of a New Purely Refractive Extended Depth of Focus IOL-Daniel Chang DH, MD. Data showed strong intermediate vision, some near vision gained and broader range of clear focus. Comparison of Tolerance to Refractive Error of a New Purely Refractive Extended Depth of Focus IOL and Standard Monofocal IOL; Vance M. Thompson, MD. Data showed 94% distance vision corrected at 20/25 or better and 97% patient satisfaction.